When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

P1, N=17, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=80 --> 17

P3, N=255, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.

P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028

T-cell engager therapies, including bispecific T-cell engagers and the immune-mobilizing monoclonal T-cell receptor against cancer tebentafusp, are an emerging class of anticancer immunotherapy, with rapid expansion of the class since initial approval of blinatumomab in 2014 and with distinct dermatologic adverse events increasingly recognized across agents. Tebentafusp and talquetamab demonstrate highest rates of notable dermatologic toxicity reflecting on-target off-tumor cutaneous effects...Across agents, most dermatologic adverse events can be managed with topical corticosteroids, emollients, antihistamines, or brief courses of systemic corticosteroids without requiring treatment discontinuation. Recognition of these agent-specific and mechanistically linked patterns is essential for dermatologists as T-cell engager therapies become increasingly integrated into oncology practice.

During talquetamab treatment, 35.8% (130/363) of participants developed anti-drug antibodies, including 18.2% (66/363) with neutralizing antibodies, across both recommended doses, and no clinically meaningful impact of immunogenicity on talquetamab pharmacokinetics, efficacy, or safety was observed. Talquetamab has received accelerated approval (US) and conditional marketing authorization (EU) with further ongoing investigation as monotherapy or in combination regimens across various MM treatment settings.

P1/2, N=28, Not yet recruiting, Janssen Cilag International

P2, N=230, Not yet recruiting, Janssen Research & Development, LLC

P2, N=30, Active, not recruiting, PETHEMA Foundation | Trial primary completion date: Mar 2025 --> Mar 2026

P2, N=210, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2029 --> May 2030 | Trial primary completion date: Apr 2026 --> May 2030

P2, N=510, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> Jun 2027